Aurum Biosciences Ltd is a Scottish based clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and spinal cord injury (SCI). Follow-on indications include heart disease, cardiac arrest, oncology, traumatic brain injury (TBI) and inflammatory conditions.
Aurum’s lead product ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. ABL-101, which has previously received MHRA clinical trial approval in stroke, is planned for phase 2a trials in stroke, spinal cord injury and inflammation imaging in 2025.
Aurum which has funding from The Wellcome Trust, InnoScot, Tricapital Angel Investors, Scottish Enterprise and a number of notable international and private investors has recently completed its final seed funding round in January 2024.